ICMJE DISCLOSURE FORM

Date: April 27th, 2022 Your Name: Bin Du

Manuscript Title: Learning for the next pandemic: when high level evidence is not readily available...

Manuscript number (if known): JTD-22-201-R3

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

esearch grant 2021-I2M-1-062 and 2020-I2M-2-005
esearch grant 2021-I2M-1-062 and 2020-I2M-2-005
esearch grant 2020YFC0841300, 2021YFC0863100, and 021YFC2500801
months

3	Royalties or licenses	XNone	
4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
	meetings and, or traver		
8	Patents planned, issued or	XNone	
	pending		
_	Participation on a Data	X None	
9			
9	· · · · · · · · · · · · · · · · · · ·		
9	Safety Monitoring Board or		
	Safety Monitoring Board or Advisory Board		
10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role	I sit on advisory boards of	
	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society,	I sit on advisory boards of National Health	
	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy	I sit on advisory boards of National Health Commission of the	
	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society,	I sit on advisory boards of National Health Commission of the People's Republic of China	
	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy	I sit on advisory boards of National Health Commission of the	
	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy	I sit on advisory boards of National Health Commission of the People's Republic of China for management of	
	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy	I sit on advisory boards of National Health Commission of the People's Republic of China for management of	
	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy	I sit on advisory boards of National Health Commission of the People's Republic of China for management of	
	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy	I sit on advisory boards of National Health Commission of the People's Republic of China for management of	
10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	I sit on advisory boards of National Health Commission of the People's Republic of China for management of COVID-19	
10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options	I sit on advisory boards of National Health Commission of the People's Republic of China for management of COVID-19 XNone	
10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment,	I sit on advisory boards of National Health Commission of the People's Republic of China for management of COVID-19	
10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical	I sit on advisory boards of National Health Commission of the People's Republic of China for management of COVID-19 XNone	
10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other	I sit on advisory boards of National Health Commission of the People's Republic of China for management of COVID-19 XNone	
10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services	I sit on advisory boards of National Health Commission of the People's Republic of China for management of COVID-19 XNoneXNone	
10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-	I sit on advisory boards of National Health Commission of the People's Republic of China for management of COVID-19 XNone	
11 12	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services	I sit on advisory boards of National Health Commission of the People's Republic of China for management of COVID-19 XNoneXNone	

Please summarize the above conflict of interest in the following box:

The author receives research grants from Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (CIFMS) from Chinese Academy of Medical Sciences and Peking Union Medical College (2021-I2M-1-062 and 2020-I2M-2-005) and Ministry of Science and Technology of the People's Republic of China (2020YFC0841300, 2021YFC0863100, and 2021YFC2500801). He sits on advisory boards of National Health Commission of the People's Republic of China for management of COVID-19.

Please place an "X" next to the following statement to indicate your agreement:						
X_ I certify that I have answered every question and have not altered the wording of any of the questions on t form.						

ICMJE DISCLOSURE FORM

Date:April 27 th , 2022
Your Name:Chunting Wang
Manuscript Title:_ Learning for the next pandemic: when high level evidence is not readily available
Manuscript number (if known): JTD-22-201-R3

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		

Please summarize the above conflict of interest in the following box:

The author has no conflicts of interest to declare.				

Please place an "X" next to the following statement to indicate your agreement:

__X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date:April 27 th , 2022
Your Name:Mervyn Singer
Manuscript Title:_ Learning for the next pandemic: when high level evidence is not readily available
Manuscript number (if known): JTD-22-201-R3

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		

Please summarize the above conflict of interest in the following box:

The author has no conflicts of interest to declare.					

Please place an "X" next to the following statement to indicate your agreement:

__X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.